Recent updates on Glucokinase activators for the treatment of type 2 diabetes mellitus

Mini-Reviews in Medicinal Chemistry

Volumn 14, Issue 7, 2014, Pages 585-602

  Grewal, Ajmer Singh ^a   Sekhon, Bhupinder Singh ^b   Lather, Viney ^a  

^a JCDM College of Pharmacy   (India)

^b PCTE Institute of Pharmacy   (India)

Author keywords

Benzamides; Diabetes mellitus; Glucokinase; Glucokinase activators; T2DM

Indexed keywords

2 AMINO 4 FLUORO 5 (1 METHYL 1H IMIDAZOL 2 YLTHIO) N (3 (TRIFLUOROMETHYL)PHENYL]BANZAMIDE; 2 AMINO 5 (4 METHYL 4H 1,2,4 TRIAZOL 3 YLTHIO) N (4 METHYLTHIAZOL 2 YL)BENZAMIDE; 3 (1 HYDROXYPROPAN 2 YLOXY) 5 (4 (METHYLSULFONYL)PHENOXY) N (THIAZOL 2 YL)BENZAMIDE; 3 (1METHOXYPROPAN 2 YLOXY 5 (1 PHENYLPROPEN 2 YLOXY)BENZAMIDE)NICOTINIC ACID; 3 (4 (CYCLOPROPANESULFONYL)PHENOXY) 5 (3 METHYLBUT 2 ENYLOXY) N (THIAZOL 2 YL)BENZAMIDE; 3 (4 (METHYLSULFONYL)BENZYL N (1 ((METHOXYMETHOXY)METHYL) 1H PYRAZOL 3YL) 5 (3 METHYLPYRIDIN 2 YL)BENZAMIDE; 3 ISOPROPOXY 5 (4 (METHYLSULFONYL)PHENOXY N (4 METHYLTHIAZOL 2 YL)BENZAMIDE; 4 (5 (AZETIDINE 1 CARBONYL)PYRAZIN 2 YLOXY) 2 ETHYL N (5 METHYLPYRAZIN 2 YL) 2H INDAZOLE 6 CARBOXAMIDE; 5 (2 CARBAMOYLPHENYL) N (5,6 DIHYDRO 4H CYCLOPENTA[ D]THIAZOL 2 YL) 2 ETHYLTHIOPHENE 3 CARBOXAMIDE; 5 (3 FLUOROBENZYLOXY) 2 (2 ETHOXYETHOXY) N (PYRIDINE 2 YL)BENZAMIDE; 6 (3 (2,6 DIFLUOROPHENETHYL) 5 (1 METHOXYPROPAN 2 YLOXY)BENZAMIDE)NICOTINIC ACID; 6 (3 ISOPROPOXY 5 (2 THIOPHEN 3 YL)ETHOXY)BENZAMIDE)NICOTINIC ACID; 6 (3,5 DIFLUOROPHENOXY) 5 (1 METHOXYPROPAN 2 YLOXY)BENZAMIDE)NICOTINIC ACID; 6 (4H 1,2,4 TRIAZOL 3YLTHIO) 3 (4 FLUOROPHENYLTHIO) N THIAZOL 2 YL)PICOLINAMIDE; ANTIDIABETIC AGENT; AZD1656; AZD6370; GLUCOKINASE ACTIVATOR; GLUCOKINASE ACTIVATOR 50; GLUCOKINASE ACTIVATOR A2; GLUCOSE 6 PHOSPHATE; GLYCOGEN; LY2121260; MEGLITINIDE; METHYL 6 (3 CYCLOHEXYL 2 (4 (METHYLSULFONYL)BENZAMIDE)PROPANAMIDE)NICOTINATE; PIRAGLIATIN; PSN 010; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG; YH GLUCOKINASE ACTIVATOR; ENZYME ACTIVATOR; GLUCOKINASE;

ARTICLE; BRAIN; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PREGNANCY DIABETES MELLITUS; ANIMAL; CHEMISTRY; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM;

ANIMALS; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATION; ENZYME ACTIVATORS; GLUCOKINASE; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84906246631     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557514666140722082713     Document Type: Article

References (130)

1. Leutholz, B.C.; Ripoll, I. Exercise and Disease Management, 2nd ed.; CRC Press: Boca Raton, 2011.
2. Ahmed, A.M. History of Diabetes Mellitus. Saudi Med. J., 2002, 23(4), 373-378.
3. Kumar, P.; Clark, M. Clinical Medicine, 7th ed.; Elsevier Saunders: London, 2009.
4. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1997, 20, 1183-1197.
5. World Health Organization Study Group. Diabetes Mellitus: WHO Technical Report, Series 727. Geneva: World Health Organization, 1985.
6. DeFronzo, R.A.; Ferrannini, E.; Keen, H.; Zimmet, P. International Textbook of Diabetes Mellitus, 3rd ed.; John Wiley & Sons Ltd.: Chichester, 2004.
7. Guyton, A.C.; Hall, J.E. Textbook of Medical Physiology, 11th ed.; Elsevier Saunders: London, 2006.
8. Olokoba, A.B.; Obateru O.A.; Olokoba, L.B. Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Med. J., 2012, 27(4), 269-273.
9. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27(5), 1047-1053.
10. Mohan, V.; Anbalagan, V.P. Expanding role of the Madras Diabetes Research Foundation - Indian Diabetes Risk Score in clinical practice. Indian J. Endocr. Metab., 2013, 17, 31-36.
11. Pal, M. Medicinal Chemistry Approaches for Glucokinase Activation to Treat Type 2 Diabetes. Current Med. Chem., 2009, 16(29), 3858-3874.
12. Ripsin, C.M.; Kang, H.; Urban, R.J. Management of blood glucose in type 2 diabetes mellitus. Am. Fam. Physician, 2009, 79(1), 29-36.
13. Salim, B. Diabetes mellitus and its treatment. Int. J. Diabetes Metab., 2005, 13, 111-134.
14. Fowler, M.J. Microvascular and Macrovascular Complications of Diabetes. Clin. Diabetes, 2008, 26(2), 77-82.
15. Korytkowski, M.T. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride. Pharmacotherapy, 2004, 24(5), 606-620.
16. Rafiq, M.; Flanagan, S.E.; Patch, A.M.; Shields, B.M.; Ellard, S.; Hattersley, A.T. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care, 2008, 31(2), 204-209.
17. Setter, S.M.; Iltz, J.L.; Thams, J.; Campbell, R.K. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy. Clin. Ther., 2003, 25(12), 2991-3026.
18. Bailey, C.J.; Turner, R.C. Metformin. N. Engl. J. Med., 1996, 334(9), 574-579.
19. Bailey, C.J. Biguanides and NIDDM. Diabetes Care, 1992, 15(6), 755-772.
20. Pittas, A.G.; Greenberg, A.S. Thiazolidinediones in the treatment of type 2 diabetes. Expert Opin. Pharmacother., 2002, 3(5), 529-540.
21. Lebovitz, H.E. Alpha-glucosidase inhibitors. Endocrinol. Metab. Clin. North Am., 1997, 26(3), 539-551.
22. Van De Laar, F.A.; Lucassen, P.L.; Akkermans, R.P.; Van De Lisdonk, E.H.; Rutten, G.E.; Van Weel, C. Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care, 2005, 28, 154-163.
23. Nathan, D.M. Initial management of glycemia in type 2 diabetes mellitus. N. Engl. J. Med., 2002, 347(17), 1342-1349.
24. Tripathy, K.D. Essentials of Medical Pharmacology. 6th ed.; Jaypee Brothers Medical Publishers (P) Ltd.: New Delhi, 2008.
25. Waring, W.S. Antidiabetic drugs. Medicine, 2012, 40(2), 98-99.
26. Fyfe, M.C.T.; Procter, M.J. Glucokinase activators as potential antidiabetic agents possessing superior glucose-lowering efficacy. Drugs Fut., 2009, 34(8), 641-653.
27. Grimsby, J.; Berthel, S.J., Sarabu, R. Glucokinase activators for the potential treatment of type 2 diabetes. Curr. Top. Med. Chem., 2008, 8(17), 1524-1532.
28. Matschinsky, F.M. Assessing the potential of glucokinase activators in diabetes therapy. Nat. Rev. Drug. Discov., 2009, 8(5), 399-416.
29. Reimann, F.; Gribble, F.M. Glucose-Sensing in Glucagon-Like Peptide-1-Secreting Cells. Diabetes, 2002, 51(9), 2757-2763.
30. Matschinsky, F.M.; Zelent, B.; Doliba, N.; Li, C.; Vanderkooi, J.M.; Naji, A.; Sarabu, R.; Grimsby, J. Glucokinase activators for diabetes therapy. Diabetes Care, 2011, 34(Suppl 2), S236-S243.
31. Vinuela, E.; Salas, M.; Sols, A. Glucokinase and hexokinase in liver in relation to glycogen synthesis. J. Biol. Chem., 1963, 238(3), 1175-1177.
32. Sharma, C.; Manjeshwar, R.; Weinhouse, S. Hormonal and dietary regulation of hepatic glucokinase. Adv. Enzyme Regul., 1964, 2, 189-200.
33. Sols, A.; Salas, M.; Vinuela, E. Induced biosynthesis of liver glucokinase. Adv. Enzyme. Regul., 1964, 2, 177-188.
34. Walker, D.G.; Rao, S. The role of glucokinase in the phosphorylation of glucose by rat liver. Biochem. J., 1964, 90(2), 360-368.
35. Matschinsky, F.M.; Ellerman, J.E. Metabolism of glucose in the islets of Langerhans. J. Biol. Chem., 1968, 243(10), 2730-2736.
36. Matschinsky, F.M.; Porte, D. Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics. F1000 Med. Rep., 2010, 2, 43.
37. Matschinsky, F.M.; Magnuson, M.A.; Zelent, D.; Jetton, T.L.; Doliba, N.; Han, Y.; Taub, R.; Grimsby, J. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes, 2006, 55(1), 1-12.
38. Priyadarsini, R.L.; Namratha, J.R.; Reddy, D.R.S. Glucokinase activators: A glucose sensor role in pancreatic islets and hepatocyte. Int. J. Pharm. Pharm. Sci., 2012, 4(2), 81-87.
39. Meglasson, M.D.; Matschinsky, F.M. New perspectives on pancreatic islet glucokinase. Am. J. Physiol., 1984, 246, E1-13.
40. Meglasson, M.D.; Matschinsky, F.M. Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes Metab. Rev., 1986, 2(3-4), 163-214.
41. Matschinsky, F.; Liang, Y.; Kesavan, P.; Wang, L.; Froguel, P.; Velho, G.; Cohen, D.; Permutt, M.A.; Tanizawa, Y.; Jetton, T.L.; Niswender, K.; Magnuson, M.A. Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J. Clin. Invest., 1993, 92(5), 2092-2098.
42. Iynedjian, P.B. Molecular physiology of mammalian glucokinase. Cell Mol. Life Sci., 2009, 66(1), 27-42.
43. Massa, M.; Gagliardino, J.J.; Francini, F. Liver glucokinase: An overview on the regulatory mechanisms of its activity. IUBMB Life, 2011, 63(1), 1-6.
44. Van Schaftingen, E., Detheux, M., Veiga da Cunha, M. Short-term control of glucokinase activity: role of a regulatory protein. FASEB J., 1994, 8, 414-419.
45. Pal, M. Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug Discov. Today, 2009, 14(15-16), 784-792.
46. Tahrani, A.A.; Bailey, C.J.; Prato, S.D.; Barnett, A.H. Management of type 2 diabetes: new and future developments in treatment. The Lancet, 2011, 378(9786), 182-197.
47. Al-Hasani, H.; Tschop, M.H.; Cushman, S.W. Two birds with one stone: novel glucokinase activator stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose metabolism. Mol. Interv., 2003, 3(7), 367-370.
48. Matschinsky, F.M. Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes, 2002, 51(Suppl 3), S394-404.
49. Perseghin, G. Exploring the in vivo mechanisms of action of glucokinase activators in type 2 diabetes. J. Clin. Endocrinol. Metab., 2010, 95(11), 4871-4873.
50. Coghlan, M.; Leighton, B. Glucokinase activators in diabetes management. Expert Opin. Investig. Drugs, 2008, 17(2), 145-167.
51. Kamata, K.; Mitsuya, M.; Nishimura, T.; Eiki, J.; Nagata, Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure, 2004, 12(3), 429-438.
52. Liu, S.; Ammirati, M.J.; Song, X.; Knafels, J.D.; Zhang, J.; Greasley, S.E.; Pfefferkorn, J.A.; Qiu, X. Insights into mechanism of glucokinase activation: observation of multiple distinct protein conformations. J. Biol. Chem., 2012, 287(17), 13598-13610.
53. Petit, P.; Antoine, M.; Ferry, G.; Boutin, J.A.; Lagarde, A.; Gluais, L.; Vincentelli, R.; Vuillard, L. The active conformation of human glucokinase is not altered by allosteric activators. Acta. Crystallogr. D Biol. Crystallogr., 2011, 67, 929-935.
54. Johnson, D.; Shepherd, R.M.; Gill, D.; Gorman, T.; Smith, D.M.; Dunne, M.J. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator. Diabetes, 2007, 56(6), 1694-1702.
55. Choi, J.M.; Seo, M.H.; Kyeong, H.H.; Kim, E.; Kim, H.S. Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase. Proc. Natl. Acad. Sci. (USA), 2013, 110(25), 10171-10176.
56. Anderka, O.; Boyken, J.; Aschenbach, U.; Batzer, A.; Boscheinen, O.; Schmoll, D. Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors. J. Biol. Chem., 2008, 283(46), 31333-31340.
57. Grimsby, J.; Sarabu, R.; Corbett, W.L.; Haynes, N.-E.; Bizzarro, F.T.; Coffey, J.W.; Guertin, K.R.; Hilliard, D.W.; Kester, R.F.; Mahaney, P.E.; Marcus, L.; Qi, L.; Spence, C.L.; Tengi, J.; Magnuson, M.A.; Chu, C.A.; Dvorozniak, M.T.; Matschinsky, F.M.; Grippo, J.F. Allosteric activators of glucokinase: potential role in diabetes therapy. Science, 2003, 301(5631), 370-373.
58. Matschinsky, F.M.; Zelent, B.; Doliba, N.M.; Kaestner, K.H.; Vanderkooi, J.M.; Grimsby, J.; Berthel, S.J.; Sarabu, R. In: Handbook of Experimental Pharmacology; Mathias Schwanstecher, Ed.; Springer: London, 2011, 203, 357-401.
59. Bonadonna, R.C.; Heise, T.; Arbet-Engels, C.; Kapitza, C.; Avogaro, A.; Grimsby, J.; Zhi, J.; Grippo, J.F.; Balena, R. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J. Clin. Endocrinol. Metab., 2010, 95(11), 5028-5036.
60. Sarabu, R.; Tilley, J.W.; Grimsby, J. In: Accounts in Drug Discovery: Case Studies in Medicinal Chemistry; Joel Barrish, Percy Carter, Peter Cheng, Robert Zahler, Ed.; The Royal Society of Chemistry: 2011, 51-70.
61. Sarabu, R.; Bizzarro, F.T.; Corbett, W.L.; Dvorozniak, M.T.; Geng, W.; Grippo, J.F.; Haynes, N.E.; Hutchings, S.; Garofalo, L.; Guertin, K.R.; Hilliard, D.W.; Kabat, M.; Kester, R.F.; Ka, W.; Liang, Z.; Mahaney, P.E.; Marcus, L.; Matschinsky, F.M.; Moore, D.; Racha, J.; Radinov, R.; Ren, Y.; Qi, L.; Pignatello, M.; Spence, C.L.; Steele, T.; Tengi, J.; Grimsby, J. Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients. Med. Chem., 2012, 55(16), 7021-7036.
62. De Ceuninck, F.; Kargar, C.; Ilic, C.; Caliez, A.; Rolin, J.O.; Umbdenstock, T.; Vinson, C.; Combettes, M.; de Fanti, B.; Harley, E.; Sadlo, M.; Lefevre, A.L.; Broux, O.; Wierzbicki, M.; Fourquez, J.M.; Perron-Sierra, F.; Kotschy, A.; Ktorza A. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br. J. Pharmacol., 2013, 168(2), 339-353.
63. Rees, M.G.; Gloyn, A.L. Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour? Br. J. Pharmacol., 2013, 168(2), 335-338.
64. McKerrecher, D.; Allen, J.V.; Bowker, S.S.; Boyd, S.; Caulkett, P.W.R.; Currie, G.S.; Davies, C.D.; Fenwick, M.L.; Gaskin, H.; Grange, E.; Hargreaves, R.B.; Hayter, B.R.; James, R.; Johnson, K.M.; Johnstone, C.; Jones, C.D.; Lackie, S.; Rayner, J.W.; Walker, R.P. Discovery, synthesis and biological evaluation of novel glucokinase activators. Bioorg. Med. Chem. Lett., 2005, 15(8), 2103-2106.
65. McKerrecher, D.; Allen, J.V.; Caulkett, P.W.; Donald, C.S.; Fenwick, M.L.; Grange, E.; Johnson, K.M.; Johnstone, C.; Jones, C.D.; Pike, K.G.; Rayner, J.W.; Walker, R.P. Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. Bioorg. Med. Chem. Lett., 2006, 16(10), 2705-2709.
66. Nishimura, T.; Iino, T.; Mitsuya, M.; Bamba, M.; Watanabe, H.; Tsukahara, D.; Kamata, K.; Sasaki, K.; Ohyama, S.; Hosaka, H.; Futamura, M.; Nagata, Y.; Eiki, J. Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators. Bioorg. Med. Chem. Lett., 2009, 19(5), 1357-1360.
67. Iino, T.; Tsukahara, D.; Kamata, K.; Sasaki, K.; Ohyama, S.; Hosaka, H.; Hasegawa, T.; Chiba, M.; Nagata, Y.; Eiki, J.; Nishimura, T. Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators. Bioorg. Med. Chem., 2009, 17(7), 2733-2743.
68. Iino, T.; Hashimoto, N.; Sasaki, K.; Ohyama, S.; Yoshimoto, R.; Hosaka, H.; Hasegawa, T.; Chiba, M.; Nagata, Y.; Eiki, J.; Nishimura, T. Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy. Bioorg. Med. Chem., 2009, 17(11), 3800-3809.
69. Iino, T.; Hashimoto, N.; Hasegawa, T.; Chiba, M.; Eiki, J.; Nishimura, T. Metabolic activation of N-thiazol-2-yl benzamide as glucokinase activators: Impacts of glutathione trapping on covalent binding. Bioorg. Med. Chem. Lett., 2010, 20(5), 1619-1622.
70. Zhang, L.; Li, H.; Zhu, Q.; Liu, J.; Chen, L.; Leng, Y.; Jiang, H.; Liu, H. Benzamide derivatives as dual-action hypoglycemic agents that inhibit glycogen phosphorylase and activate glucokinase. Bioorg. Med. Chem., 2009, 17(20), 7301-7312.
71. Pike, K.G.; Allen, J.V.; Caulkett, P.W.; Clarke, D.S.; Donald, C.S.; Fenwick, M.L.; Johnson, K.M.; Johnstone, C.; McKerrecher, D.; Rayner, J.W.; Walker, R.P.; Wilson, I. Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life. Bioorg. Med. Chem. Lett., 2011, 21(11), 3467-3470.
72. Li, Y.Q.; Zhang, Y.L.; Hu, S.Q.; Wang, Y.L.; Song, H.R.; Feng, Z.Q.; Lei, L.; Liu, Q.; Shen, Z.F. Design, synthesis and biological evaluation of novel glucokinase activators. Chin. Chem. Lett., 2011, 22(1), 73-76.
73. Mao, W.; Ning, M.; Liu, Z.; Zhu, Q.; Leng, Y.; Zhang, A. Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators. Bioorg. Med. Chem., 2012, 20(9), 2982-2991.
74. Zhang, L.; Chen, X.; Liu, J.; Zhu, Q.; Leng, Y.; Luo, X.; Jiang, H.; Liu, H. Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase. Eur. J. Med. Chem., 2012, 58, 624-639.
75. Park, K.; Lee, B.M.; Kim, Y.H.; Han, T.; Yi, W.; Lee, D.H.; Choi, H.H.; Chong, W.; Lee, C.H. Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem. Lett., 2013, 23(2), 537-542.
76. Park, K.; Lee, B.M.; Hyun, K.H.; Lee, D.H.; Choi, H.H.; Kim, H.; Chong, W.; Kim, K.B.; Nam, S.Y. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem., 2014, 22(7), 2280-2293.
77. Mitsuya, M.; Kamata, K.; Bamba, M.; Watanabe, H.; Sasaki, Y.; Sasaki, K.; Ohyama, S.; Hosaka, H.; Nagata, Y.; Eiki, J.; Nishimura, T. Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators. Bioorg. Med. Chem. Lett., 2009, 19(10), 2718-2721.
78. Lang, M.; Seifert, M.H.; Wolf, K.K.; Aschenbrenner, A.; Baumgartner, R.; Wieber, T.; Trentinaglia, V.; Blisse, M.; Tajima, N.; Yamashita, T.; Vitt, D.; Noda, H. Discovery and hit-to-lead optimization of novel allosteric glucokinase activators. Bioorg. Med. Chem. Lett., 2011, 21(18), 5417-5422.
79. Pfefferkorn, J.A.; Tu, M.; Filipski, K.J.; Guzman-Perez, A.; Bian, J.; Aspnes, G.E.; Sammons, M.F.; Song, W.; Li, J.C.; Jones, C.S.; Patel, L.; Rasmusson, T.; Zeng, D.; Karki, K.; Hamilton, M.; Hank, R.; Atkinson, K.; Litchfield, J.; Aiello, R.; Baker, L.; Barucci, N.; Bourassa, P.; Bourbounais, F.; D'Aquila, T.; Derksen, D.R.; MacDougall, M.; Robertson, A. The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem. Lett., 2012, 22(23), 7100-7105.
80. Pfefferkorn, J.A.; Lou, J.; Minich, M.L.; Filipski, K.J.; He, M.; Zhou, R.; Ahmed, S.; Benbow, J.; Perez, A.G.; Tu, M.; Litchfield, J.; Sharma, R.; Metzler, K.; Bourbonais, F.; Huang, C.; Beebe, D.A.; Oates, P.J. Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle. Bioorg. Med. Chem. Lett., 2009, 19(12), 3247-3252.
81. Bebernitz, G.R.; Beaulieu, V.; Dale, B.A.; Deacon, R.; Duttaroy, A.; Gao, J.; Grondine, M.S.; Gupta, R.C.; Kakmak, M.; Kavana, M.; Kirman, L.C.; Liang, J.; Maniara, W.M.; Munshi, S.; Nadkarni, S.S.; Schuster, H.F.; Stams, T.; Denny, I.S.; Taslimi, P.M.; Vash, B.; Caplan, S.L. Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J. Med. Chem., 2009, 52(19), 6142-6152.
82. Li, F.; Zhu Q; Zhang, Y.; Feng, Y.; Leng, Y.; Zhang, A. Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazole-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl) propanamides as glucokinase activators. Bioorg. Med. Chem., 2010, 18(11), 3875-3884.
83. Pfefferkorn, J.A.; Guzman-Perez, A.; Litchfield, J.; Aiello, R.; Treadway, J.L.; Pettersen, J.; Minich, M.L.; Filipski, K.J.; Jones, C.S.; Tu, M.; Aspnes, G.; Risley, H.; Bian, J.; Stevens, B.D,; Bourassa, P.; Dquila, T.; Baker, L.; Barucci, N.; Robertson, A.S.; Bourbonais, F.; Derksen, D.R.; Macdougall, M.; Cabrera, O.; Chen, J.; Lapworth, A.L.; Landro, J.A.; Zavadoski, W.J.; Atkinson, K.; Haddish-Berhane, N.; Tan, B.; Yao, L.; Kosa, R.E.; Varma, M.V.; Feng, B.; Duignan, D.B.; El-Kattan, A.; Murdande, S.; Liu, S.; Ammirati, M.; Knafels, J.; Dasilva-Jardine, P.; Sweet, L.; Liras, S.; Rolph, T.P. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J. Med. Chem., 2012, 55(3), 1318-1333.
84. Cheruvallath, Z.S.; Gwaltney, S.L.; Sabat, M.; Tang, M.; Feng, J.; Wang, H.; Miura, J.; Guntupalli, P.; Jennings, A.; Hosfield, D.; Lee, B.; Wu, Y. Design, synthesis and SAR of novel glucokinase activators. Bioorg. Med. Chem. Lett., 2013, 23(7), 2166-2171.
85. Bonn, P.; Brink, D.M.; Fagerhag, J.; Jurva, U.; Robb, G.R.; Schnecke, V.; Henriksson, A.S.; Waring, M.J.; Westerlund, C. The discovery of a novel series of glucokinase activators based on a pyrazolopyrimidine scaffold. Bioorg. Med. Chem. Lett., 2012, 22(24), 7302-7305.
86. Sidduri, A.; Grimsby, J.S.; Corbett, W.L.; Sarabu, R.; Grippo, J.F.; Lou, J.; Kester, R.F.; Dvorozniak, M.; Marcus, L.; Spence, C.; Racha, J.K.; Moore, D.J. 2,3-Disubstituted acrylamides as potent glucokinase activators. Bioorg. Med. Chem. Lett., 2010, 20(19), 5673-5676.
87. Heusera, S.; Barretta, D.G.; Berga, M.; Bonnierb, B.; Kahla, A.; Puentec, M.L.D.L.; Oramd, N.; Riedla, R.; Roettiga, U.; Gilc, G.S.; Segera, E.; Stegglesd, D.J.; Wannera, J.; Weichert, A.G. Synthesis of novel cyclopropylic sulfones and sulfonamides acting as glucokinase activators. Tetrahedron Lett., 2006, 47(16), 2675-2678.
88. Ye, N.; Xu, X.; Li, F.; Ning, M.; Liu, Z.; Cao, Y.; Leng, Y.; Zhang, A. Investigation on the oxidation of aryl oxiranylmethanols and the synthesis of 2-aryl-N-thiazolyl-oxirane-2-carboxamides as glucokinase activators. Tetrahedron Lett., 2012, 53(35), 4738-4742.
89. Iino, T.; Sasaki, Y.; Bamba, M.; Mitsuya, M.; Ohno, A.; Kamata, K.; Hosaka, H.; Maruki, H.; Futamura, M.; Yoshimoto, R.; Ohyama, S.; Sasaki, K.; Chiba, M.; Ohtake, N.; Nagata, Y.; Eiki, J.; Nishimura, T. Discovery and structure-activity relationships of a novel class of quinazoline glucokinase activators. Bioorg. Med. Chem. Lett., 2009, 19(19), 5531-5538.
90. Song, H.; Tian, K.; Lei, L.; Shen, Z.; Liu, S.; Zhang, L.; Song, H.; Jinc, X.; Feng, Z. Novel N-(pyrimidin-4-yl)thiazol-2-amine derivatives as dual-action hypoglycemic agents that activate GK and PPARγ. Acta. Pharmaceutica. Sinica. B, 2011, 1(3), 166-171.
91. Hinklin, R.J.; Boyd, S.A.; Chicarelli, M.J.; Condroski, K.R.; DeWolf, W.E.; Lee, P.A.; Lee, W.; Singh, A.; Thomas, L.; Voegtli, W.C.; Williams, L.; Aicher, T.D. Identification of a new class of glucokinase activators through structure-based design. J. Med. Chem., 2013, 56(19), 7669-7678.
92. Castelhano, A.L.; Dong, H.; Fyfe, M.C.; Gardner, L.S.; Kamikozawa, Y.; Kurabayashi, S.; Nawano, M.; Ohashi, R.; Procter, M.J.; Qiu, L.; Rasamison, C.M.; Schofield, K.L.; Shah, V.K.; Ueta, K.; Williams, G.M.; Witter, D.; Yasuda, K. Glucokinase-activating ureas. Bioorg. Med. Chem. Lett., 2005, 15(5), 1501-1504.
93. Zhang, L.; Tian, K.; Li, Y.; Lei, L.; Qin, A.; Zhang, L.; Song, H.; Huo, L.; Zhang, L.; Jin, X.; Shen, Z.; Feng, Z. Novel phenyl-urea derivatives as dual-target ligands that can activate both GK and PPARγ. Acta. Pharmaceutica. Sinica. B, 2012, 2(6), 588-597.
94. Li, Y.; Tian, K.; Qin, A.; Zhang, L.; Huo, L.; Lei, L.; Shen, Z.; Song, H.; Feng, Z. Discovery of novel urea derivatives as dual-target hypoglycemic agents that activate glucokinase and PPARγ. Eur. J. Med. Chem., 2014, 76, 182-192.
95. Ishikawa, M.; Nonoshita, K.; Ogino, Y.; Nagae, Y.; Tsukahara, D.; Hosaka, H.; Maruki, H.; Ohyama, S.; Yoshimoto, R.; Sasaki, K.; Nagata, Y.; Eiki, J.; Nishimura, T. Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators. Bioorg. Med. Chem. Lett., 2009, 19(15), 4450-4454.
96. Takahashi, K.; Hashimoto, N.; Nakama, C.; Kamata, K.; Sasaki, K.; Yoshimoto, R.; Ohyama, S.; Hosaka, H.; Maruki, H.; Nagata, Y.; Eiki, J.; Nishimura, T. The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators. Bioorg. Med. Chem., 2009, 17(19), 7042-7051.
97. Filipski, K.J.; Guzman-Perez, A.; Bian, J.; Perreault, C.; Aspnes, G.E.; Didiuk, M.T.; Dow, R.L.; Hank, R.F.; Jones, C.S.; Maguire, R.J.; Tu, M.; Zeng, D.; Liu, S.; Knafels, J.D.; Litchfield, J.; Atkinson, K.; Derksen, D.R.; Bourbonais, F.; Gajiwala, K.S.; Hickey, M.; Johnson, T.O.; Humphries, P.S.; Pfefferkorn, J.A. Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif. Bioorg. Med. Chem. Lett., 2013, 23(16), 4571-4578.
98. Marles, R.J.; Farnsworth, N.R. Antidiabetic plants and their active constituents. Phytomedicine, 1995, 2(2), 137-189.
99. Hikino, H.; Ishiyama, M.; Suzuki, Y.; Konno, C. Mechanisms of hypoglycemic activity of ganoderan B: a glycan of Ganoderma lucidum fruit bodies. Planta Med., 1989, 55(5), 423-428.
100. Kang, Y.J.; Jung, U.J.; Lee, M.K.; Kim, H.J.; Jeon, S.M.; Park, Y.B.; Chung, H.G.; Baek, N.I.; Lee, K.T.; Jeong, T.S.; Choi M.S. Eupatilin, isolated from Artemisia princeps Pampanini, enhances hepatic glucose metabolism and pancreatic beta-cell function in type 2 diabetic mice. Diabetes Res. Clin. Pract., 2008, 82(1), 25-32.
101. Qian-Cutrone, J.; Ueki, T.; Huang, S.; Mookhtiar, K.A.; Ezekiel, R.; Kalinowski, S.S.; Brown, K.S.; Golik, J.; Lowe, S.; Pirnik, D.M.; Hugill, R.; Veitch, J.A.; Klohr, S.E.; Whitney, J.L.; Manly, S.P. Glucolipsin A and B, two new glucokinase activators produced by Streptomyces purpurogeniscleroticus and Nocardia vaccinii. J. Antibiot., 1999, 52(3), 245-55.
102. Mahmoodi, M.; Zarei, S.; Rezaeian, M.; Arababadi, M.K.; Ghasemi, H.; Khoramdelazad, H.; Rezayati, N.; Hasanshahi, G.; Hosseini-Zijoud, S.-M. Persian Article ID Shallot (Allium hirtifolium Boiss) Extract Elevates Glucokinase (GCK) Activity and Gene Expression in Diabetic Rats. Am. J. Plant Sci., 2013, 4(7), 1393-1399.
103. Mehdi, M.; Javad, H.; Seyed-Mostafa, H.Z.; Mohammadreza, M.; Ebrahim, M. The effect of Persian shallot (Allium hirtifolium Boiss.) extract on blood sugar and serum levels of some hormones in diabetic rats. Pak. J. Pharm. Sci., 2013, 26(2), 397-402.
104. Rao, V.P.; Madhavi, K.; Naidu, M.D.; Gan, S.H. Rhinacanthus nasutus Improves the Levels of Liver Carbohydrate, Protein, Glycogen, and Liver Markers in Streptozotocin-Induced Diabetic Rats. Evid. Based Complement.Alternat. Med., 2013, 2013, Article ID 102901, 7 pages.
105. Pfefferkorn, J.A. Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes. Expert Opin. Drug Discov., 2013, 8(3), 319-330.
106. Sarabu, R.; Berthel, S.J.; Kester, R.F.; Tilley, J.W. Novel glucokinase activators: a patent review (2008 -2010). Expert Opin. Ther. Pat., 2011, 21(1), 13-33.
107. Filipski, K.J.; Futatsugi, K.; Pfefferkorn, J.A.; Stevens, B.D. Glucokinase activators. Pharm. Pat. Anal., 2012, 1(3), 301-311.
108. Charlotte Harrison, C. Patent watch. Nat. Rev. Drug Discov., 2009, 8, 350-351.
109. Pfefferkorn, J.A.; Ling, A.L. Benzofuranyl Derivatives. U.S. Patent US 20130252973 A1, September 26, 2013.
110. Benbow, J.W.; Lou, J.; Pfefferkorn, J.A.; Tu, M.M. Substituted heteroaryls. U.S. Patent 20130165452 A1, June 27, 2013.
111. Houze, J.B.; Dransfield, P.; Pattaropong, V.; Du, X.; Fu, Z.; Lai, S.; Park, J.; Jiao, X.; Kohn, T.J.; Aicher, T.D.; Boyd, S.A.; Bencsik, J.; Condroski, K.R.; Hinklin, R.J.; Kraser, C.F.; Pratt, S.; Singh, A.; Wenglowsky, S.M.; Boys, M.L.; Chicarelli, M.J.; Mohr, P.J.; Cardozo, M.G. Urea compounds as GKA activators. World Intellectual Property Organization 2013086397 A1, June 13, 2013.
112. Haynes, N.E.; Scott, N.R.; Tilley, J.W. Pyridone glucokinase activators. U.S. Patent 20130131113 A1, May 23, 2013.
113. Sarabu, R. 3-Oxo-3,9-dihydro-1h-chromeno[2,3-C]pyrroles as glucokinase activators. European Patent 2582706 A1, April 24, 2013.
114. Meng, W.; Cheng, P.T.W. Novel glucokinase activators and methods of using same. U.S. Patent 20130029939 A1, January 31, 2013.
115. Aicher, A.D.; Boyd, S.A.; Chicarelli, M.J.; Condroski, K.R.; Hinklin, R.J.; Singh, A. 2-Aminopyridine analogs as glucokinase activators. European Patent 2543667 A1, January 09, 2013.
116. Berthel, S.J.; Kester, R.F.; Orzechowski, L. Isoindolinone derivatives. World Intellectual Property Organization 2012150202 A1, November 08, 2012.
117. Aicher, T.D.; Boyd, S.A.; Chicarelli, M.J.; Condroski, K.R.; Fell, J.B.; Fischer, J.P.; Gunawardana, I.W.; Hinklin, R.J.; Singh, A.; Turner, T.M.; Wallace, E.M. Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus. U.S. Patent 20120277242 A1, November 01, 2012.
118. Berthel, S.J.; Chen, L.; Corbett, W.L.; Feng, L.; Haynes, N.E.; Kester, R.F.; So, S.S.; Tilley, J.W. Azaindole glucokinase activators. European Patent 2513103 A1, October 24, 2012.
119. Cheruvallath, Z.; Feng, J.; Guntupalli, P.; Gwaltney, S.L.; Miura, J.; Sabat, M.; Tang, M.; Wang, H. Glucokinase Activators. U.S. Patent 20120252814 A1, October 04, 2012.
120. Cheruvallath, Z.; Gwaltney, S.L.; Jennings, A.J.; Sabat, M.; Stafford, J.A.; Tang, M.; Wang, H. Glucokinase Activators. U.S. Patent 20120225887 A1, Sepember 06, 2012.
121. Bhuniya, D.; Deshpande, A.; Kandalkar, S.; Kobal, B.; Kurhade, S.; Vyavahare, V.; Kaduskar, R. Acetamide derivatives as glucokinase activators, their process and medicinal applications. U.S. Patent 20120214735 A1, August 23, 2012.
122. Jain, M.R.; Kharul, R.; Patel, P.R. Substituted benzamide derivatives as glucokinase (GK) activators. U.S. Patent 20120184544 A1, July 19, 2012.
123. Yi, W.H.; Han, T.D.; Lee, K.Y.; Kim, Y.H.; Jung, E.H.; Lee, D.H.; Park, Y.H.; Min, K.N.; Kim, J.; Lee, B.K. Novel glucokinase activators and processes for the preparation thereof. U.S. Patent 20120178765 A1, July 12, 2012.
124. Christiansen, L.B.; Lau, J.; Murray, A.; Vedso, P. Urea Glucokinase Activators. U.S. Patent US 20120165375 A1, June 28, 2012.
125. Kharul, R. Disubstituted benzamide derivatives as glucokinase (GK) activators. U.S. Patent US 20120149704 A1, June 14, 2012.
126. Ryono, D.E.; Cheng, P.T.W.; Bolton, S.A.; Chen, S.; Shi, Y.; Meng, W.; Tino, J.A.; Sulsky, R.B. Novel glucokinase activators and methods of using same. U.S. Patent 20120142636 A1, June 07, 2012.
127. Andrews, R.C.; Ankersen, M.; Christen, D.P.; Cooper, J.T.; Jeppesen, L.; Kristiansen, M.; Lau, J.; Lundbeck, J.M.; Murray, A.; Polisetti, D.R.; Santhosh, K.C.; Subramanian, G.; Valcarce-Lopez, M.C.; Vedso, P. Heteroaryl-ureas and their use as glucokinase activators. European Patent 2444397 A1, April 25, 2012.
128. Cho, M.K.; Kim, H.J.; Kim, S.H.; Kim, K.H.; Lee, S.B.; Park, H.S.; Yoon, S.H. Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient. U.S. Patent 20120088760 A1, April 12, 2012.
129. Corbett, J.W.; Guzman-Perez, A.; Pfefferkorn, J.A.; Mike, M.T. Substituted indazole amides and their use as glucokinase activators. European Patent 2406230 A1, January 18, 2012.
130. Szlyk, B.; Braun, C.R.; Ljubicic, S.; Patton, E.; Bird, G.H.; Osundiji, M.A.; Matschinsky, F.M.; Walensky, L.D.; Danial, N.N. A phospho-BAD BH3 helix activates glucokinase by a mechanism distinct from that of allosteric activators. Nat. Struct. Mol. Biol., 2014, 21(1), 36-42.